Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Exenatide on 24-hour Heart Rate in Type 2 Diabetes
2007-002691-33Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide BID with Placebo BID (2 arms). Primary endpoint: Mean 24-hour heart rate change from baseline to Week 12. Started Jun 2007; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-002691-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002691-33.